Digital Therapeutics (DTx) are evidence-based therapeutic interventions delivered as mobile software applications. They undergo rigorous clinical and regulatory review, ensuring the same high standards of efficacy and safety as with traditional drugs. A DTx can be prescribed by a physician alongside a drug or therapy or as a stand-alone treatment.
The comprehensive DTx will soon be available as a reimbursable prescription DiGA in Germany under the DVG law. The DTx is currently undergoing clinical trial and will be commercialized in collaboration with Pfizer.
The comprehensive DTx will provide treatment for currently under treated symptoms associated with IPF such as depression and anxiety, improving patient's quality of life.
With a patient-centric mentality, we are driven by our goal of delivering targeted personalized care. Our novel DTx treatments are developed in collaboration with patient groups and deliver targeted, personalized care to patients with overlooked symptoms.